Brief: Achilles Therapeutics Provides Interim Phase I/IIA Update On Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma
04/04/2024 12:22
April 4 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS PROVIDES INTERIM PHASE I/IIA UPDATE
ON
CLONAL NEOANTIGEN REACTIVE T CELLS IN ADVANCED NSCLC AND
MELANOMA INCLUDING FIRST PATIENTS DOSED WITH ENHANCED HOST
CONDITIONING
* ACHILLES THERAPEUTICS PLC: PROTOCOLS UPDATED TO EVALUATE
BENEFIT
OF ENHANCED HOST CONDITIONING, WITH FURTHER DATA EXPECTED IN 2H
2024
* ACHILLES THERAPEUTICS PLC: OBSERVED TOLERABILITY PROFILES
REMAIN
FAVORABLE AND SIMILAR TO STANDARD TIL THERAPY
Source text for Eikon: ID:nGNX1p50ly
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement